GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:14 2024-04-19 am EDT 5-day change 1st Jan Change
1,599 GBX +0.98% Intraday chart for GSK plc -2.71% +10.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix MT
GSK: positive clinical results for gonorrhea CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade CI
GSK: shingles virus effective for over 10 years CF
GSK hails data on Shingles vaccine and gonorrhoea treatment AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial MT
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin CI
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2% MT
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review MT
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate CI
GSK: vaccine accepted for FDA review CF
GSK's latest meningitis vaccine accepted for review by US regulator AN
GSK Says FDA Accepts GSK Meningitis Vaccine Candidate File RE
US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review MT
Pfizer RSV shot meets goals in trial of high-risk adults under age 60 RE
GSK : Barclays sticks Neutral ZD
Barclays Lifts GSK PT, Maintains Equalweight Rating MT
Wizz Air raised; HSBC cuts Rentokil to 'hold' AN
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers MT
GSK : Barclays reiterates its Neutral rating ZD
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs RE
GSK : Berenberg gives a Buy rating ZD
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
15.99 GBP
Average target price
20.06 GBP
Spread / Average Target
+25.44%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. Berenberg Lifts GSK PT, Maintains Buy Rating